Compare Crispr Therapeutics AG (CRSP) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Carparts.Com Inc — how do they compare? Crispr Therapeutics AG trades at $51.2 (market cap $4.88B), while Carparts.Com Inc trades at $8.59 (market cap $66.42M). The key difference: Crispr Therapeutics AG is far larger — about 73.5× Carparts.Com Inc's market cap, and Carparts.Com Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Carparts.Com Inc for 45 Days on average.
| CRSP | PRTS | |
|---|---|---|
Market Cap | $4.88B | $66.42M |
Volume | 2,861,747 | 40,287 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $10.00 |
52-Week Low | $44.34 | $3.88 |
Typical Hold Time | 77 Days | 45 Days |
Enterprise Value | $3.30B | $79.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
CarParts.com (PRTS) trades at $8.695, up 0.99% with a bullish technical signal. The company shows improving quarterly earnings performance, beating expectations in recent quarters, though remains unprofitable with negative margins. Revenue has declined from $676M in 2023 to $548M in 2025, but net losses are narrowing. Analyst sentiment is positive with 60% buy ratings, while technical indicators show bullish moving averages and neutral oscillators.
The outlook suggests potential recovery as earnings improve and losses narrow, supported by analyst optimism. Key risks include persistent negative cash flow, competitive pressures in auto parts e-commerce, and execution challenges in returning to profitability. The stock offers speculative upside if the company can sustain its earnings beat trend and stabilize revenue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
